ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1136

Association of Serum Uromodulin with Mortality and Cardiovascular Disease in the Elderly – The Cardiovascular Health Study

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Steubl, Dominik, Tufts Medical Center, Tufts University, Boston, Massachusetts, United States
  • Buzkova, Petra, UW, Seattle, Washington, United States
  • Garimella, Pranav S., UCSD, San Diego, California, United States
  • Ix, Joachim H., UCSD, San Diego, California, United States
  • Devarajan, Prasad, Cincinnati Children's Hospital, Cincinnati, Ohio, United States
  • Bennett, Michael R., Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
  • Chaves, Paulo H. M., Florida International University, Miami, Florida, United States
  • Shlipak, Michael, San Francisco VA Medical Center, San Francisco, California, United States
  • Sarnak, Mark J., Tufts Medical Center, Boston, Massachusetts, United States

Uromodulin is released by renal tubular cells into the serum (sUMOD) and urine. Lower urine UMOD has been linked to mortality and cardiovascular disease but much less is known about sUMOD. We evaluated the association of sUMOD with those outcomes in community-dwelling older adults.


We measured sUMOD in a random subcohort of 933 participants enrolled in the Cardiovascular Health Study. The association of sUMOD with all-cause mortality, incident heart failure (HF) and incident CVD (myocardial infarction, stroke and mortality due to coronary disease or stroke) were evaluated using multivariable Cox regression, adjusting for study participants’ demographics, estimated glomerular filtration rate (eGFR), albuminuria and CVD risk factors. Generalized additive models with splines were used to address the functional form of sUMOD with outcomes. Due to non-linear associations of sUMOD with all outcomes, 2.5% of the values on either end of the sUMOD distribution were excluded from the analyses, limiting the range of sUMOD to 34.3 - 267.1 ng/ml.


The mean age was 78±5 years, 40% were male, and 15% were non-white. Mean sUMOD level was 127±64 ng/ml, eGFR was 63 ml/min/1.73 m2 and 42% had CKD defined as eGFR<60 ml/min/1.73 m2. Patients in the lower sUMOD ranges had lower eGFR and higher albuminuria. During a median follow-up of 9.9 years, 805 patients died, 283 developed HF and 274 CVD. In multivariable analysis higher sUMOD was independently associated with lower mortality and CVD, and a trend for HF (Table).


Low sUMOD is independently associated with mortality and CVD in the elderly.


  • Other NIH Support